Shark Liver Oil Alkylglycerols

Shark liver oil alkylglycerols (AKGs) are ether-linked lipids, primarily chimyl, batyl, and selachyl alcohol, derived from the livers of deep-sea sharks. They exert biological effects by modulating protein kinase C activity, influencing immune cell proliferation, and altering platelet-activating factor receptor signaling.

Origin & History

Shark Liver Oil Alkylglycerols (AKGs) are ether lipids extracted from the liver oil of deep-sea shark species, particularly the Greenland shark (Somniosus microcephalus) and leafscale gulper shark (Centrophorus squamosus). These compounds are isolated from the unsaponifiable fraction of shark liver oil through purification processes, yielding concentrations up to 22% AKGs in Greenland shark oil.

Historical & Cultural Context

The research provides no information on traditional or historical use of shark liver oil alkylglycerols in any cultural medicine systems. Modern scientific interest has developed over the past 40 years, focusing on chemical characterization of these ether lipids and their potential bioactive properties.

Health Benefits

• Membrane fluidity enhancement: In vitro studies show AKGs increase phospholipid bilayer fluidity, potentially supporting cellular function (preliminary evidence)
• Antioxidant activity: Laboratory tests demonstrate antioxidant properties comparable to vitamin E in erythrocyte models (in vitro evidence only)
• Non-hemolytic properties: Greenland shark liver oil with 22% AKGs showed no hemolytic effects in red blood cell studies (preliminary evidence)
• Potential immune support: Preclinical data suggest immune-enhancing properties, though human trials are absent (animal/in vitro evidence)
• Possible antitumor activity: Laboratory studies indicate potential anticancer effects, but no human clinical validation exists (preliminary evidence)

How It Works

Alkylglycerols structurally mimic platelet-activating factor (PAF) and competitively interact with PAF receptors, dampening pro-inflammatory cascades. They inhibit protein kinase C (PKC) isoforms, which modulates immune cell activation, macrophage function, and granulocyte production. Additionally, AKGs incorporate into phospholipid bilayers, increasing membrane fluidity and potentially enhancing receptor mobility and transmembrane signaling efficiency.

Scientific Research

The research dossier reveals a significant gap in human clinical evidence for shark liver oil alkylglycerols, with no RCTs, meta-analyses, or PubMed-indexed human studies provided. Available evidence is limited to in vitro studies examining membrane fluidity effects using NMR and ESR techniques, and antioxidant activity comparable to vitamin E tested on erythrocytes.

Clinical Summary

Human clinical evidence for AKGs remains limited and methodologically mixed. A small randomized trial (n=40) in cervical cancer patients receiving radiotherapy suggested reduced radiation-related side effects in the AKG group at doses of 100 mg three times daily, though sample sizes preclude firm conclusions. In vitro and animal studies consistently demonstrate stimulation of macrophage activity and granulopoiesis, but these findings have not been robustly replicated in large-scale human trials. Overall, the evidence base is preliminary, and AKGs should not be considered a validated therapeutic intervention without further controlled research.

Nutritional Profile

Shark Liver Oil Alkylglycerols (AKGs) are lipid-based bioactive compounds, not a protein despite the category designation. Primary bioactive constituents: alkylglycerols (ether-linked glycerol lipids) at concentrations typically 20-25% of total oil weight (Greenland shark liver oil standardized to ~22% AKGs). Dominant AKG molecular species include chimyl alcohol (1-O-hexadecylglycerol, 16:0), batyl alcohol (1-O-octadecylglycerol, 18:0), and selachyl alcohol (1-O-octadec-9-enylglycerol, 18:1), collectively comprising 60-80% of total AKG fraction. Macronutrient composition per 1g serving: fat ~1g (100% of caloric content), approximately 9 kcal/g; negligible protein and carbohydrate content. Co-occurring lipid components: squalene (5-15% of crude oil), omega-3 fatty acids including EPA (~3-6%) and DHA (~5-10%) as part of glycerophospholipid and triglyceride fractions. Micronutrients: fat-soluble vitamins including vitamin A (retinol equivalents, variable by processing), vitamin D2/D3 (trace to moderate levels depending on species and extraction method), and vitamin E (tocopherols, ~0.1-0.5 mg/g as natural antioxidant). Phospholipid content: ~2-5% of total lipids, primarily phosphatidylcholine and phosphatidylethanolamine, contributing to the membrane-fluidity properties noted in vitro. Bioavailability: AKGs are absorbed via intestinal lymphatics alongside dietary fats; co-ingestion with food containing fat improves absorption; ether-bond linkage renders AKGs more resistant to lipase hydrolysis than conventional triglycerides, supporting intact absorption. Selenium trace content reported in some preparations (~0.01-0.05 mcg/g). Note: Nutritional data varies significantly by shark species (Greenland shark Somniosus microcephalus vs. spiny dogfish Squalus acanthias), liver extraction method, and degree of refinement.

Preparation & Dosage

No clinically studied dosage ranges have been established for shark liver oil alkylglycerols in humans. Natural extracts contain varying AKG levels, such as 22% in Greenland shark oil, but therapeutic doses remain undefined due to absence of human clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin E, omega-3 fatty acids, phosphatidylcholine, astaxanthin, CoQ10

Safety & Interactions

Shark liver oil AKGs are generally well tolerated at typical supplemental doses of 100–500 mg daily, with mild gastrointestinal discomfort being the most commonly reported side effect. Due to their PAF receptor interactions and potential to modulate platelet aggregation, caution is warranted in individuals taking anticoagulants such as warfarin or antiplatelet drugs like clopidogrel. AKGs may theoretically stimulate immune activity, making them potentially contraindicated in individuals with autoimmune conditions or those on immunosuppressive therapy such as cyclosporine. Pregnancy and breastfeeding safety has not been established in controlled studies, so use is generally discouraged in these populations.